Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Neuroscience Antibodies and Assays Market by Product (Consumables, Instruments), by Technology (Immunochemistry/Immunoassays, Molecular Diagnostics, Clinical Chemistry, Other Technologies), by Application (Research, In Vitro Diagnostics, Drug Discovery and Development) and by End Users (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Hospitals and Diagnostic Centers): Global Opportunity Analysis and Industry Forecast, 2023-2032

A10297

Pages: NA

Charts: NA

Tables: NA

Neuroscience is a diversified sector, which needs an integrated analysis of various organs, tissues, and cell types, by the use of various techniques. The future of research and developments in the neuroscience field depends on the antibodies, assays, and immunodetection.

Biomarkers are detected reagents based on the detection are accessible for tissue and cell types, responses measured to targeted therapies, and disease states. These markers are exceedingly certain and very strong immunoprobes. Western blotting is considered as another immunodetection technique for tissue and cell lysates, and are been upgraded by membrane technology.

There are various streams in the neuroscience antibodies & assay market based on their characteristics:

1.    Structure & Function- Neural stem cells help in the differentiation of cells on three major types in the central nervous system: astrocytes, neurons, and oligodendrocytes.

2.    Development- Nervous system complexity needs a precise and intricate developmental plan.

3.    Systems- The nervous systems are very complex but are very functional. These systems operate the whole of the body systems.

4.    Diseases- Various diseases are linked to the neuroscience segment like Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Alzheimer’s syndrome, multiple sclerosis (MS), and others

COVID-19 scenario analysis:

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.

Owing to such factors, COVID 19 is expected to have a significant impact on the Neuroscience Antibodies & Assays market.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis:

A significant increase in the incidences of neurological diseases, the rising number of pharmaceutical and biotechnology manufacturers, and their investments in neuroscience research are the major drivers for the neuroscience antibodies and assays market. Additionally, the R & D programs run by these manufacturers are creating new opportunities for antibodies and assays market.

The increasing demand for the antibodies owing to the new drug target and the potentials in it, like structural protein in the brain, molecules signaling are also causing a positive effect on the neuroscience Antibodies and Assays market.

On the other hand, strict regulatory policies by and many reported cases of unpropitious immune response against the antibodies is the major challenge for the neuroscience antibodies and assays market.

New product launches and acquisitions to flourish the market:

On December 2nd, 2019, Neurocrine Biosciences licensed and co-developed Xenon Pharmaceuticals Phase-I epilepsy candidate XEN901 which is a treatment for toddlers suffering from neurological  disorders.

On May 29th, 2020, Takeda secured a positive CHMP Opinion for its presentation for a pre-filled syringe named TAKHZYRO. This syringe will be used as a preventive therapy for Hereditary Angioedema Attacks.

Surge in usage in pharmaceutical and biotechnology companies applications:

Biotechnology and pharmaceutical companies, research and academic institutes, hospitals, and diagnostic centers are the major end-users of the neuroscience antibodies and assays market. Among them, the biotechnology and pharmaceutical companies are the biggest consumers. Various drug development and discovery activities along with the government initiatives are creating a demand for the neuroscience antibodies and assays market.

Key benefits of the report:

  • This study presents the analytical depiction of the global Neuroscience Antibodies & Assays industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the global Neuroscience Antibodies & Assays market share.
  • The current market is quantitatively analyzed to highlight the global market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the Neuroscience Antibodies & Assays market.
  • The report provides a detailed global Neuroscience Antibodies & Assays market analysis based on competitive intensity and how the competition will take shape in the coming years.

Questions answered in the Neuroscience Antibodies & Assays Market research report:

  • What are the leading market players active in the Neuroscience Antibodies & Assays market?
  • What the current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the Neuroscience Antibodies & Assays market?
  • What are the projections for the future that would help in taking further strategic steps? 

Key Market Segments

  • By Product
    • Consumables
      • Reagents
        • Media & Sera
        • Stains & Dyes
        • Fixatives
        • Buffers
        • Solvents
        • Probes
        • Enzymes, Proteins, and Peptides
        • Other Reagents
      • Antibodies
        • Primary antibodies
        • Secondary Antibodies
      • Assay Kits
    • Instruments
      • Microplate Readers
      • Immunoassay Analyzers
      • Other Instruments
  • By Technology
    • Immunochemistry/Immunoassays
      • ELISA
      • Western Blotting
      • Others Immunoassays Technologies
    • Molecular Diagnostics
    • Clinical Chemistry
    • Other Technologies
  • By Application
    • Research
    • In Vitro Diagnostics
    • Drug Discovery and Development
  • By End Users
    • Pharmaceutical and Biotechnology Companies
    • Academic and Research Institutes
    • Hospitals and Diagnostic Centers
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA


Key Market Players

  • Cell Signaling Technology
  • BioLegend
  • Thermo Fisher Scientific Inc.
  • GenScript
  • Abcam
  • Santa Cruz Biotechnology
  • Bio-Rad
  • Merck KGaA
  • Rockland Immunochemicals
  • F. Hoffmann La Roche
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Consumables

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

      • 4.2.4. Reagents

        • 4.2.4.1. Market Size and Forecast
        • 4.2.4.2. Media and Sera

          • 4.2.4.2.1. Market Size and Forecast
        • 4.2.4.2. Stains and Dyes

          • 4.2.4.2.1. Market Size and Forecast
        • 4.2.4.2. Fixatives

          • 4.2.4.2.1. Market Size and Forecast
        • 4.2.4.2. Buffers

          • 4.2.4.2.1. Market Size and Forecast
        • 4.2.4.2. Solvents

          • 4.2.4.2.1. Market Size and Forecast
        • 4.2.4.2. Probes

          • 4.2.4.2.1. Market Size and Forecast
        • 4.2.4.2. Enzymes, Proteins, and Peptides

          • 4.2.4.2.1. Market Size and Forecast
        • 4.2.4.2. Other Reagents

          • 4.2.4.2.1. Market Size and Forecast
      • 4.2.4. Antibodies

        • 4.2.4.1. Market Size and Forecast
        • 4.2.4.2. Primary antibodies

          • 4.2.4.2.1. Market Size and Forecast
        • 4.2.4.2. Secondary Antibodies

          • 4.2.4.2.1. Market Size and Forecast
      • 4.2.4. Assay Kits

        • 4.2.4.1. Market Size and Forecast
    • 4.3. Instruments

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

      • 4.3.4. Microplate Readers

        • 4.3.4.1. Market Size and Forecast
      • 4.3.4. Immunoassay Analyzers

        • 4.3.4.1. Market Size and Forecast
      • 4.3.4. Other Instruments

        • 4.3.4.1. Market Size and Forecast
  • CHAPTER 5: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Technology

    • 5.2. Immunochemistry/Immunoassays

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

      • 5.2.4. ELISA

        • 5.2.4.1. Market Size and Forecast
      • 5.2.4. Western Blotting

        • 5.2.4.1. Market Size and Forecast
      • 5.2.4. Others Immunoassays Technologies

        • 5.2.4.1. Market Size and Forecast
    • 5.3. Molecular Diagnostics

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Clinical Chemistry

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Other Technologies

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Application

    • 6.2. Research

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. In Vitro Diagnostics

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Drug Discovery And Development

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USERS

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By End Users

    • 7.2. Pharmaceutical And Biotechnology Companies

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Academic And Research Institutes

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

    • 7.4. Hospitals And Diagnostic Centers

      • 7.4.1. Key Market Trends, Growth Factors and Opportunities

      • 7.4.2. Market Size and Forecast, By Region

      • 7.4.3. Market Share Analysis, By Country

  • CHAPTER 8: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY REGION

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By Region

    • 8.2. North America

      • 8.2.1. Key Market Trends and Opportunities

      • 8.2.2. Market Size and Forecast, By Product

      • 8.2.3. Market Size and Forecast, By Technology

      • 8.2.4. Market Size and Forecast, By Application

      • 8.2.5. Market Size and Forecast, By End Users

      • 8.2.6. Market Size and Forecast, By Country

      • 8.2.7. U.S. Neuroscience Antibodies And Assays Market

        • 8.2.7.1. Market Size and Forecast, By Product
        • 8.2.7.2. Market Size and Forecast, By Technology
        • 8.2.7.3. Market Size and Forecast, By Application
        • 8.2.7.4. Market Size and Forecast, By End Users
      • 8.2.8. Canada Neuroscience Antibodies And Assays Market

        • 8.2.8.1. Market Size and Forecast, By Product
        • 8.2.8.2. Market Size and Forecast, By Technology
        • 8.2.8.3. Market Size and Forecast, By Application
        • 8.2.8.4. Market Size and Forecast, By End Users
      • 8.2.9. Mexico Neuroscience Antibodies And Assays Market

        • 8.2.9.1. Market Size and Forecast, By Product
        • 8.2.9.2. Market Size and Forecast, By Technology
        • 8.2.9.3. Market Size and Forecast, By Application
        • 8.2.9.4. Market Size and Forecast, By End Users
    • 8.3. Europe

      • 8.3.1. Key Market Trends and Opportunities

      • 8.3.2. Market Size and Forecast, By Product

      • 8.3.3. Market Size and Forecast, By Technology

      • 8.3.4. Market Size and Forecast, By Application

      • 8.3.5. Market Size and Forecast, By End Users

      • 8.3.6. Market Size and Forecast, By Country

      • 8.3.7. France Neuroscience Antibodies And Assays Market

        • 8.3.7.1. Market Size and Forecast, By Product
        • 8.3.7.2. Market Size and Forecast, By Technology
        • 8.3.7.3. Market Size and Forecast, By Application
        • 8.3.7.4. Market Size and Forecast, By End Users
      • 8.3.8. Germany Neuroscience Antibodies And Assays Market

        • 8.3.8.1. Market Size and Forecast, By Product
        • 8.3.8.2. Market Size and Forecast, By Technology
        • 8.3.8.3. Market Size and Forecast, By Application
        • 8.3.8.4. Market Size and Forecast, By End Users
      • 8.3.9. Italy Neuroscience Antibodies And Assays Market

        • 8.3.9.1. Market Size and Forecast, By Product
        • 8.3.9.2. Market Size and Forecast, By Technology
        • 8.3.9.3. Market Size and Forecast, By Application
        • 8.3.9.4. Market Size and Forecast, By End Users
      • 8.3.10. Spain Neuroscience Antibodies And Assays Market

        • 8.3.10.1. Market Size and Forecast, By Product
        • 8.3.10.2. Market Size and Forecast, By Technology
        • 8.3.10.3. Market Size and Forecast, By Application
        • 8.3.10.4. Market Size and Forecast, By End Users
      • 8.3.11. UK Neuroscience Antibodies And Assays Market

        • 8.3.11.1. Market Size and Forecast, By Product
        • 8.3.11.2. Market Size and Forecast, By Technology
        • 8.3.11.3. Market Size and Forecast, By Application
        • 8.3.11.4. Market Size and Forecast, By End Users
      • 8.3.12. Russia Neuroscience Antibodies And Assays Market

        • 8.3.12.1. Market Size and Forecast, By Product
        • 8.3.12.2. Market Size and Forecast, By Technology
        • 8.3.12.3. Market Size and Forecast, By Application
        • 8.3.12.4. Market Size and Forecast, By End Users
      • 8.3.13. Rest Of Europe Neuroscience Antibodies And Assays Market

        • 8.3.13.1. Market Size and Forecast, By Product
        • 8.3.13.2. Market Size and Forecast, By Technology
        • 8.3.13.3. Market Size and Forecast, By Application
        • 8.3.13.4. Market Size and Forecast, By End Users
    • 8.4. Asia-Pacific

      • 8.4.1. Key Market Trends and Opportunities

      • 8.4.2. Market Size and Forecast, By Product

      • 8.4.3. Market Size and Forecast, By Technology

      • 8.4.4. Market Size and Forecast, By Application

      • 8.4.5. Market Size and Forecast, By End Users

      • 8.4.6. Market Size and Forecast, By Country

      • 8.4.7. China Neuroscience Antibodies And Assays Market

        • 8.4.7.1. Market Size and Forecast, By Product
        • 8.4.7.2. Market Size and Forecast, By Technology
        • 8.4.7.3. Market Size and Forecast, By Application
        • 8.4.7.4. Market Size and Forecast, By End Users
      • 8.4.8. Japan Neuroscience Antibodies And Assays Market

        • 8.4.8.1. Market Size and Forecast, By Product
        • 8.4.8.2. Market Size and Forecast, By Technology
        • 8.4.8.3. Market Size and Forecast, By Application
        • 8.4.8.4. Market Size and Forecast, By End Users
      • 8.4.9. India Neuroscience Antibodies And Assays Market

        • 8.4.9.1. Market Size and Forecast, By Product
        • 8.4.9.2. Market Size and Forecast, By Technology
        • 8.4.9.3. Market Size and Forecast, By Application
        • 8.4.9.4. Market Size and Forecast, By End Users
      • 8.4.10. South Korea Neuroscience Antibodies And Assays Market

        • 8.4.10.1. Market Size and Forecast, By Product
        • 8.4.10.2. Market Size and Forecast, By Technology
        • 8.4.10.3. Market Size and Forecast, By Application
        • 8.4.10.4. Market Size and Forecast, By End Users
      • 8.4.11. Australia Neuroscience Antibodies And Assays Market

        • 8.4.11.1. Market Size and Forecast, By Product
        • 8.4.11.2. Market Size and Forecast, By Technology
        • 8.4.11.3. Market Size and Forecast, By Application
        • 8.4.11.4. Market Size and Forecast, By End Users
      • 8.4.12. Thailand Neuroscience Antibodies And Assays Market

        • 8.4.12.1. Market Size and Forecast, By Product
        • 8.4.12.2. Market Size and Forecast, By Technology
        • 8.4.12.3. Market Size and Forecast, By Application
        • 8.4.12.4. Market Size and Forecast, By End Users
      • 8.4.13. Malaysia Neuroscience Antibodies And Assays Market

        • 8.4.13.1. Market Size and Forecast, By Product
        • 8.4.13.2. Market Size and Forecast, By Technology
        • 8.4.13.3. Market Size and Forecast, By Application
        • 8.4.13.4. Market Size and Forecast, By End Users
      • 8.4.14. Indonesia Neuroscience Antibodies And Assays Market

        • 8.4.14.1. Market Size and Forecast, By Product
        • 8.4.14.2. Market Size and Forecast, By Technology
        • 8.4.14.3. Market Size and Forecast, By Application
        • 8.4.14.4. Market Size and Forecast, By End Users
      • 8.4.15. Rest of Asia Pacific Neuroscience Antibodies And Assays Market

        • 8.4.15.1. Market Size and Forecast, By Product
        • 8.4.15.2. Market Size and Forecast, By Technology
        • 8.4.15.3. Market Size and Forecast, By Application
        • 8.4.15.4. Market Size and Forecast, By End Users
    • 8.5. LAMEA

      • 8.5.1. Key Market Trends and Opportunities

      • 8.5.2. Market Size and Forecast, By Product

      • 8.5.3. Market Size and Forecast, By Technology

      • 8.5.4. Market Size and Forecast, By Application

      • 8.5.5. Market Size and Forecast, By End Users

      • 8.5.6. Market Size and Forecast, By Country

      • 8.5.7. Brazil Neuroscience Antibodies And Assays Market

        • 8.5.7.1. Market Size and Forecast, By Product
        • 8.5.7.2. Market Size and Forecast, By Technology
        • 8.5.7.3. Market Size and Forecast, By Application
        • 8.5.7.4. Market Size and Forecast, By End Users
      • 8.5.8. South Africa Neuroscience Antibodies And Assays Market

        • 8.5.8.1. Market Size and Forecast, By Product
        • 8.5.8.2. Market Size and Forecast, By Technology
        • 8.5.8.3. Market Size and Forecast, By Application
        • 8.5.8.4. Market Size and Forecast, By End Users
      • 8.5.9. Saudi Arabia Neuroscience Antibodies And Assays Market

        • 8.5.9.1. Market Size and Forecast, By Product
        • 8.5.9.2. Market Size and Forecast, By Technology
        • 8.5.9.3. Market Size and Forecast, By Application
        • 8.5.9.4. Market Size and Forecast, By End Users
      • 8.5.10. UAE Neuroscience Antibodies And Assays Market

        • 8.5.10.1. Market Size and Forecast, By Product
        • 8.5.10.2. Market Size and Forecast, By Technology
        • 8.5.10.3. Market Size and Forecast, By Application
        • 8.5.10.4. Market Size and Forecast, By End Users
      • 8.5.11. Argentina Neuroscience Antibodies And Assays Market

        • 8.5.11.1. Market Size and Forecast, By Product
        • 8.5.11.2. Market Size and Forecast, By Technology
        • 8.5.11.3. Market Size and Forecast, By Application
        • 8.5.11.4. Market Size and Forecast, By End Users
      • 8.5.12. Rest of LAMEA Neuroscience Antibodies And Assays Market

        • 8.5.12.1. Market Size and Forecast, By Product
        • 8.5.12.2. Market Size and Forecast, By Technology
        • 8.5.12.3. Market Size and Forecast, By Application
        • 8.5.12.4. Market Size and Forecast, By End Users
  • CHAPTER 9: COMPETITIVE LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top Winning Strategies

    • 9.3. Product Mapping Of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Top Player Positioning, 2024

  • CHAPTER 10: COMPANY PROFILES

    • 10.1. Thermo Fisher Scientific Inc.

      • 10.1.1. Company Overview

      • 10.1.2. Key Executives

      • 10.1.3. Company Snapshot

      • 10.1.4. Operating Business Segments

      • 10.1.5. Product Portfolio

      • 10.1.6. Business Performance

      • 10.1.7. Key Strategic Moves and Developments

    • 10.2. Abcam

      • 10.2.1. Company Overview

      • 10.2.2. Key Executives

      • 10.2.3. Company Snapshot

      • 10.2.4. Operating Business Segments

      • 10.2.5. Product Portfolio

      • 10.2.6. Business Performance

      • 10.2.7. Key Strategic Moves and Developments

    • 10.3. Bio-Rad

      • 10.3.1. Company Overview

      • 10.3.2. Key Executives

      • 10.3.3. Company Snapshot

      • 10.3.4. Operating Business Segments

      • 10.3.5. Product Portfolio

      • 10.3.6. Business Performance

      • 10.3.7. Key Strategic Moves and Developments

    • 10.4. Merck KGaA

      • 10.4.1. Company Overview

      • 10.4.2. Key Executives

      • 10.4.3. Company Snapshot

      • 10.4.4. Operating Business Segments

      • 10.4.5. Product Portfolio

      • 10.4.6. Business Performance

      • 10.4.7. Key Strategic Moves and Developments

    • 10.5. BioLegend

      • 10.5.1. Company Overview

      • 10.5.2. Key Executives

      • 10.5.3. Company Snapshot

      • 10.5.4. Operating Business Segments

      • 10.5.5. Product Portfolio

      • 10.5.6. Business Performance

      • 10.5.7. Key Strategic Moves and Developments

    • 10.6. Cell Signaling Technology

      • 10.6.1. Company Overview

      • 10.6.2. Key Executives

      • 10.6.3. Company Snapshot

      • 10.6.4. Operating Business Segments

      • 10.6.5. Product Portfolio

      • 10.6.6. Business Performance

      • 10.6.7. Key Strategic Moves and Developments

    • 10.7. F. Hoffmann La Roche

      • 10.7.1. Company Overview

      • 10.7.2. Key Executives

      • 10.7.3. Company Snapshot

      • 10.7.4. Operating Business Segments

      • 10.7.5. Product Portfolio

      • 10.7.6. Business Performance

      • 10.7.7. Key Strategic Moves and Developments

    • 10.8. GenScript

      • 10.8.1. Company Overview

      • 10.8.2. Key Executives

      • 10.8.3. Company Snapshot

      • 10.8.4. Operating Business Segments

      • 10.8.5. Product Portfolio

      • 10.8.6. Business Performance

      • 10.8.7. Key Strategic Moves and Developments

    • 10.9. Rockland Immunochemicals

      • 10.9.1. Company Overview

      • 10.9.2. Key Executives

      • 10.9.3. Company Snapshot

      • 10.9.4. Operating Business Segments

      • 10.9.5. Product Portfolio

      • 10.9.6. Business Performance

      • 10.9.7. Key Strategic Moves and Developments

    • 10.10. Santa Cruz Biotechnology

      • 10.10.1. Company Overview

      • 10.10.2. Key Executives

      • 10.10.3. Company Snapshot

      • 10.10.4. Operating Business Segments

      • 10.10.5. Product Portfolio

      • 10.10.6. Business Performance

      • 10.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR CONSUMABLES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR INSTRUMENTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR IMMUNOCHEMISTRY/IMMUNOASSAYS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR CLINICAL CHEMISTRY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR RESEARCH, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR IN VITRO DIAGNOSTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR HOSPITALS AND DIAGNOSTIC CENTERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 18. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 19. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 20. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 21. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 22. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 23. U.S. NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 24. U.S. NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 25. U.S. NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 26. U.S. NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 27. CANADA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 28. CANADA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 29. CANADA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 30. CANADA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 31. MEXICO NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 32. MEXICO NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 33. MEXICO NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 34. MEXICO NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 35. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 36. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 37. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 38. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 39. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 40. FRANCE NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 41. FRANCE NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 42. FRANCE NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 43. FRANCE NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 44. GERMANY NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 45. GERMANY NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 46. GERMANY NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 47. GERMANY NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 48. ITALY NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 49. ITALY NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 50. ITALY NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 51. ITALY NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 52. SPAIN NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 53. SPAIN NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 54. SPAIN NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 55. SPAIN NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 56. UK NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 57. UK NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 58. UK NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 59. UK NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 60. RUSSIA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 61. RUSSIA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 62. RUSSIA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 63. RUSSIA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 64. REST OF EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 65. REST OF EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 66. REST OF EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 67. REST OF EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 68. ASIA-PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 69. ASIA-PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 70. ASIA-PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 71. ASIA-PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 72. ASIA-PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 73. CHINA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 74. CHINA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 75. CHINA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 76. CHINA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 77. JAPAN NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 78. JAPAN NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 79. JAPAN NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 80. JAPAN NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 81. INDIA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 82. INDIA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 83. INDIA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 84. INDIA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 85. SOUTH KOREA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 86. SOUTH KOREA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 87. SOUTH KOREA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 88. SOUTH KOREA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 89. AUSTRALIA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 90. AUSTRALIA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 91. AUSTRALIA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 92. AUSTRALIA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 93. THAILAND NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 94. THAILAND NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 95. THAILAND NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 96. THAILAND NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 97. MALAYSIA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 98. MALAYSIA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 99. MALAYSIA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 100. MALAYSIA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 101. INDONESIA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 102. INDONESIA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 103. INDONESIA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 104. INDONESIA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 105. REST OF ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 106. REST OF ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 107. REST OF ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 108. REST OF ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 109. LAMEA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 110. LAMEA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 111. LAMEA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 112. LAMEA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 113. LAMEA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 114. BRAZIL NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 115. BRAZIL NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 116. BRAZIL NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 117. BRAZIL NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 118. SOUTH AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 119. SOUTH AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 120. SOUTH AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 121. SOUTH AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 122. SAUDI ARABIA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 123. SAUDI ARABIA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 124. SAUDI ARABIA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 125. SAUDI ARABIA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 126. UAE NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 127. UAE NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 128. UAE NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 129. UAE NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 130. ARGENTINA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 131. ARGENTINA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 132. ARGENTINA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 133. ARGENTINA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 134. REST OF LAMEA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 135. REST OF LAMEA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 136. REST OF LAMEA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 137. REST OF LAMEA NEUROSCIENCE ANTIBODIES AND ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 138. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
  • TABLE 139. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • TABLE 140. THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
  • TABLE 141. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
  • TABLE 142. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 143. ABCAM: KEY EXECUTIVES
  • TABLE 144. ABCAM: COMPANY SNAPSHOT
  • TABLE 145. ABCAM: OPERATING SEGMENTS
  • TABLE 146. ABCAM: PRODUCT PORTFOLIO
  • TABLE 147. ABCAM: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 148. BIO-RAD: KEY EXECUTIVES
  • TABLE 149. BIO-RAD: COMPANY SNAPSHOT
  • TABLE 150. BIO-RAD: OPERATING SEGMENTS
  • TABLE 151. BIO-RAD: PRODUCT PORTFOLIO
  • TABLE 152. BIO-RAD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 153. MERCK KGAA: KEY EXECUTIVES
  • TABLE 154. MERCK KGAA: COMPANY SNAPSHOT
  • TABLE 155. MERCK KGAA: OPERATING SEGMENTS
  • TABLE 156. MERCK KGAA: PRODUCT PORTFOLIO
  • TABLE 157. MERCK KGAA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 158. BIOLEGEND: KEY EXECUTIVES
  • TABLE 159. BIOLEGEND: COMPANY SNAPSHOT
  • TABLE 160. BIOLEGEND: OPERATING SEGMENTS
  • TABLE 161. BIOLEGEND: PRODUCT PORTFOLIO
  • TABLE 162. BIOLEGEND: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 163. CELL SIGNALING TECHNOLOGY: KEY EXECUTIVES
  • TABLE 164. CELL SIGNALING TECHNOLOGY: COMPANY SNAPSHOT
  • TABLE 165. CELL SIGNALING TECHNOLOGY: OPERATING SEGMENTS
  • TABLE 166. CELL SIGNALING TECHNOLOGY: PRODUCT PORTFOLIO
  • TABLE 167. CELL SIGNALING TECHNOLOGY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 168. F. HOFFMANN LA ROCHE: KEY EXECUTIVES
  • TABLE 169. F. HOFFMANN LA ROCHE: COMPANY SNAPSHOT
  • TABLE 170. F. HOFFMANN LA ROCHE: OPERATING SEGMENTS
  • TABLE 171. F. HOFFMANN LA ROCHE: PRODUCT PORTFOLIO
  • TABLE 172. F. HOFFMANN LA ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 173. GENSCRIPT: KEY EXECUTIVES
  • TABLE 174. GENSCRIPT: COMPANY SNAPSHOT
  • TABLE 175. GENSCRIPT: OPERATING SEGMENTS
  • TABLE 176. GENSCRIPT: PRODUCT PORTFOLIO
  • TABLE 177. GENSCRIPT: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 178. ROCKLAND IMMUNOCHEMICALS: KEY EXECUTIVES
  • TABLE 179. ROCKLAND IMMUNOCHEMICALS: COMPANY SNAPSHOT
  • TABLE 180. ROCKLAND IMMUNOCHEMICALS: OPERATING SEGMENTS
  • TABLE 181. ROCKLAND IMMUNOCHEMICALS: PRODUCT PORTFOLIO
  • TABLE 182. ROCKLAND IMMUNOCHEMICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 183. SANTA CRUZ BIOTECHNOLOGY: KEY EXECUTIVES
  • TABLE 184. SANTA CRUZ BIOTECHNOLOGY: COMPANY SNAPSHOT
  • TABLE 185. SANTA CRUZ BIOTECHNOLOGY: OPERATING SEGMENTS
  • TABLE 186. SANTA CRUZ BIOTECHNOLOGY: PRODUCT PORTFOLIO
  • TABLE 187. SANTA CRUZ BIOTECHNOLOGY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET
  • FIGURE 3. SEGMENTATION NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALNEUROSCIENCE ANTIBODIES AND ASSAYS MARKET
  • FIGURE 11. NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR CONSUMABLES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR INSTRUMENTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SEGMENTATION, BY BY TECHNOLOGY
  • FIGURE 15. NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR IMMUNOCHEMISTRY/IMMUNOASSAYS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 20. NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR RESEARCH, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR IN VITRO DIAGNOSTICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SEGMENTATION, BY BY END USERS
  • FIGURE 24. NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 26. NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR HOSPITALS AND DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 27. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 28. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 29. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 30. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 31. COMPETITIVE DASHBOARD
  • FIGURE 32. COMPETITIVE HEATMAP: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET
  • FIGURE 33. TOP PLAYER POSITIONING, 2024
  • FIGURE 34. THERMO FISHER SCIENTIFIC INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 35. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 36. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 37. ABCAM: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. ABCAM: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. ABCAM: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. BIO-RAD: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. BIO-RAD: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. BIO-RAD: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. MERCK KGAA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. MERCK KGAA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. MERCK KGAA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. BIOLEGEND: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. BIOLEGEND: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. BIOLEGEND: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. CELL SIGNALING TECHNOLOGY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. CELL SIGNALING TECHNOLOGY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. CELL SIGNALING TECHNOLOGY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. F. HOFFMANN LA ROCHE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. F. HOFFMANN LA ROCHE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. F. HOFFMANN LA ROCHE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 55. GENSCRIPT: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 56. GENSCRIPT: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 57. GENSCRIPT: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 58. ROCKLAND IMMUNOCHEMICALS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 59. ROCKLAND IMMUNOCHEMICALS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 60. ROCKLAND IMMUNOCHEMICALS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 61. SANTA CRUZ BIOTECHNOLOGY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 62. SANTA CRUZ BIOTECHNOLOGY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 63. SANTA CRUZ BIOTECHNOLOGY: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Neuroscience Antibodies and Assays Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue